Semaglutide Improves Insulin Sensitivity in Patients With Schizophrenia, Prediabetes, and Obesity Treated With Second-Generation Antipsychotics: Findings From the HISTORI Trial
Posted inDiabetes & Endocrinology news Psychiatry

Semaglutide Improves Insulin Sensitivity in Patients With Schizophrenia, Prediabetes, and Obesity Treated With Second-Generation Antipsychotics: Findings From the HISTORI Trial

In a 30-week randomized trial, semaglutide improved insulin sensitivity, reduced insulin resistance, lowered fasting glucose, and produced substantial weight loss in patients with schizophrenia and prediabetes taking second-generation antipsychotics.
Circulating MicroRNA Scores May Distinguish Cellular and Antibody-Mediated Heart Transplant Rejection With High Accuracy
Posted inCardiology news Pathology & Lab Medicine/Bệnh học

Circulating MicroRNA Scores May Distinguish Cellular and Antibody-Mediated Heart Transplant Rejection With High Accuracy

A prospective multicenter study found circulating microRNA rejection scores identified ACR and AMR with strong diagnostic performance and prognostic value, supporting their development as noninvasive tools to reduce reliance on surveillance biopsy after heart transplantation.
Higher Lipoprotein(a) Marks Greater Coronary Risk Without Prior MI or Stroke, While Evolocumab Delivers Similar Relative Benefit and Larger Absolute Gains
Posted inCardiology Internal Medicine news

Higher Lipoprotein(a) Marks Greater Coronary Risk Without Prior MI or Stroke, While Evolocumab Delivers Similar Relative Benefit and Larger Absolute Gains

In VESALIUS-CV, elevated baseline Lp(a) independently predicted major coronary events, especially MI, in patients without prior MI or stroke. Evolocumab reduced relative risk similarly across Lp(a) levels, with numerically greater absolute benefit in those with higher Lp(a).